Skip to main content
Skip to content
Case File
efta-01450729DOJ Data Set 10Other

EFTA01450729

Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01450729
Pages
1
Persons
0
Integrity

Summary

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
William Blair & Company, LLC. Exhibit 1 ARIAD Pharmaceuticals, Inc. Sum-of-Parts Fair Value (dollars in thousands) Drug Peak Sales Stage of Development Estimated Launch Date Probability of Commercialization Percentage of Sales to Company Probability. Adjusted NPV Value per Share Percentage of Fair Value Iclusig-CML 9746.822 Marketed January 2013/ 100% 100% $1,843,975 $9.85 83.4% Worldwide July 2013 AP28113—ALK* NSCLC S280918 Phase Ifl I 1-12 2016 81% 100% $325,268 $1.74 14.7% Worldwide Subtotal $2,189,243 $11.59 98.2% Net Cash at Yearend 2014 $63,406 $0.34 2.9% Net Present Value of additional Gain (Loss)' ($22,727) ($0.12) (1.0%) Sum-of-Parts Fair Value $2,209,922 $11.81 100.0% - Includes costs nal *Golly reined to programs above Sources. Company reports and %ma'am Emir 8 Company. L L.C. estimates 5 I Y. Katherine Xu, Ph.D. CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL DB-SDNY-0 106554 SDNY_GM_00252738 EFTA01450729

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.